Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Innomedica

Request full access

Pharmaceuticals efficiently targeted

Bern, SwitzerlandFounded 2000Biotech & Life Sciences

About Innomedica

Innomedica operates as a Swiss biopharmaceutical company, concentrating on the advancement of drug delivery systems through nanotechnology. The firm was initially established as a finance company in 2000. A pivotal shift occurred in January 2013 when it transitioned into an operationally independent pharmaceutical entity, a move catalyzed by the acquisition of the Japanese company YAMAZAKI-DDS Co., Ltd. This acquisition provided Innomedica with access to a nanotechnology platform that had undergone over two decades of research and patenting.

The company's core business revolves around a proprietary, patent-protected nanocarrier technology platform. This technology utilizes liposomes, which are artificially created vesicles, to encapsulate active pharmaceutical ingredients. The objective is to enable the targeted delivery of drugs to specific sites within the body, thereby improving therapeutic efficacy while simultaneously reducing side effects. The platform is designed to be versatile, capable of being used with both established clinical drugs and novel substances like RNA or proteins. Innomedica's business model includes forming international research collaborations and establishing licensing agreements to enter global markets. The company also operates its own GMP-certified 'Nanofactory' in Marly, Switzerland, ensuring control over the entire value chain from production to the final sterile product.

Innomedica's product pipeline is focused on significant therapeutic areas, primarily oncology and neurodegenerative diseases. A key development in its oncology portfolio is Talidox®, a liposomal formulation of the established chemotherapy agent doxorubicin. This product is engineered to deliver the drug directly to tumor tissue in high concentrations, potentially reducing severe side effects like heart problems, hair loss, and nausea associated with conventional chemotherapy. Clinical trials for Talidox began in November 2018 for treating advanced metastatic solid tumors, breast cancer, and ovarian cancer. In the neurology space, the company is developing a treatment for neurodegenerative conditions such as Parkinson's disease. This product utilizes a nanocarrier designed to cross the blood-brain barrier to deliver neuroprotective agents. The first Parkinson's patient was treated in a clinical study in December 2021.

Source: Dealroom company data

At a glance

Status
Operational
Employees
35
Open positions
None listed
Dealroom signal
59.6/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Pharmacy, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based, Swiss DT Biotech
Client focus
B2B, B2C

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Dec 2021 $16M $65M Undisclosed ↗
LATE VC✓Equity / VC Jul 2018 $10M $41M Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Innomedica website traffic

Latest recorded traffic for Innomedica is 920 monthly website visits, up 24.3% over the last three months. Innomedica's team declined 5.4% over the past year.

Latest monthly visits920 3-month web change+24.3% 1-year team growth-5.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Remedial HealthDigitizing the pharmaceutical supply chain in Africa Newark, United States Operational 229 $14M $32M
ten23 healthThe human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines Basel, Switzerland Operational
MimiX BiotherapeuticsAcoustic biofabrication platform for shaping tissues and organ models using sound-based cell patterning Neuchâtel, Switzerland Operational
Vaderis TherapeuticsA clinical stage biotechnology company focussed on the treatment of rare and orphan diseases caused by Vascular Malformations Basel, Switzerland Operational
TargImmune TherapeuticsDeveloping novel targeted immuno-oncology drugs Basel, Switzerland Acquired
TruepillA software-powered pharmacy of the future, serving healthcare brands worldwide delivering world-class patient experiences through API-connected healthcare infrastructure Hayward, United States Acquired
Arvelle TherapeuticsA biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Zug, Switzerland Acquired
MetrioPharmA pharmaceutical biotech company developing the first effective and safe therapy for chronic immune disorders Zurich, Switzerland Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Innomedica in the Bern ecosystem

Live from Dealroom

The Innomedica office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland · Bern HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Innomedica on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Innomedica’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.